30 November 2017

Results of 2017 Annual General Meeting Incorporating Proxy Results

 

Adelaide, Australia, 28 November 2017 – Ellex Medical Lasers Limited (ASX:ELX), a global leader in medical devices for the diagnosis and treatment of eye disease, confirms in accordance with Listing Rule 3.13.2, the results for each of the resolutions put to the Annual General Meeting held at 2:00 pm on Tuesday 28 November 2017 was as follows:

Ordinary Business

Resolution 2 – Re-election of Meera Verma as a Director

The instructions given to validly appointed proxies in respect of the Resolution were as follows:

For

Against

Open Proxies

Abstain

40,544,394

3,199,247

677,280

92,135

Result: Resolution Carried by a show of hands

Resolution 3 – Adoption of Remuneration Report

The instructions given to validly appointed proxies in respect of the Resolution were as follows:

For

Against

Open proxies

Abstain

22,758,167

2,227,811

704,280

144,979

Result: Resolution Carried by a show of hands

Resolution 4 – Ratification of Prior Share Issue Placement for Purpose of Listing Rule 7.4: Reset of 15% Threshold

The instructions given to validly appointed proxies in respect of the Resolution were as follows:

For

Against

Open usable

Abstain

21,783,490

632,046

547,300

87,178

Result: Resolution Carried by a show of hands

Resolution 5 – Approval of 10% Placement Capacity

The instructions given to validly appointed proxies in respect of the Resolution were as follows:

For

Against

Open proxies

Abstain

32,371,775

9,826,869

672,300

1,642,112

For

Against

Abstain

36,545,457

9,833,989

1,642,112

Result: Resolution Carried by a poll

Resolution 6 – Increase in the Directors’ Fee Cap

The instructions given to validly appointed proxies in respect of the Resolution were as follows:

For

Against

Open proxies

Abstain

20,074,519

3,484,939

554,780

1,720,999

Result: Resolution Carried by a show of hands

Meeting closed at 3:15pm

Maria Maieli
CFO & Company Secretary

ABOUT ELLEX

Ellex designs, develops, manufactures and sells innovative products that help eye surgeons around the world to effectively and efficiently treat eye disease. Ellex is a world leader in this field. Headquartered in Adelaide, Australia, Ellex has ophthalmic lasers and devices that treat glaucoma, retinal disease primarily caused by diabetes, secondary cataract and vitreous opacities, as well as age-related macular degeneration. Manufacturing is carried out in Adelaide, Australia and Fremont, California. Sales and service directly to eye surgeons is conducted via subsidiary offices in Minneapolis, Lyon, Berlin and Tokyo. A network of more than 50 distribution partners around the world services other markets.

For additional information about Ellex and its products, please visit www.ellex.com

For further information on Ellex please contact:

Tom Spurling, CEO
Ellex Medical Lasers Limited
3 Second Avenue, Mawson Lakes, SA, 5095
W +61 8 7074 8293 | M +61 417 818 658
tspurling@ellex.com

Maria Maieli, CFO & Company Secretary
Ellex Medical Lasers Limited
3 Second Avenue, Mawson Lakes, SA, 5095
W +61 8 7074 8200
mmaieli@ellex.com

Andrew Angus
Overland Advisers
M +61 402 823 757
andrewangus@overlandadvisers.com.au